Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial - 30/01/24
, Venkatesh Kapu, DM a, Sushmita Rath, DM a, Sravan Kumar, DM a, Anbarasan Sekar, DM a, Priyanka Patil, MSc a, Altaf Siddiqui, BPharm a, Srikanth Anne, DM a, Akash Pawar, PGD b, Sujay Srinivas, DM a, Prabhat Bhargava, DM a, Seema Gulia, ProfDM a, Vanita Noronha, ProfDM a, Amit Joshi, ProfDM a, Kumar Prabhash, ProfDM a, Shripad Banavali, ProfDM a, Rajiv Sarin, ProfMD c, Rajendra Badwe, ProfMS d, Sudeep Gupta, ProfDM aSummary |
Background |
Olanzapine is an effective antiemetic agent but it results in substantial daytime somnolence when administered at the standard dose. Our aim was to compare the efficacy of low-dose versus standard-dose olanzapine after highly emetogenic chemotherapy in patients with solid tumours.
Methods |
This was a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial done in a tertiary care referral centre in India (Tata Memorial Centre, Homi Bhabha National Institute, Mumbai). Patients aged 13–75 years with an Eastern Cooperative Oncology Group performance status of 0–2, who were receiving doxorubicin–cyclophosphamide or high-dose cisplatin for a solid tumour were eligible. Patients were randomly assigned (1:1), with block randomisation (block sizes of 2 or 4) and stratified by sex, age (≥55 or <55 years), and chemotherapy regimen, to receive low-dose (2·5 mg) oral olanzapine or standard-dose (10·0 mg) oral olanzapine daily for 4 days, in combination with a triple antiemetic regimen. Study staff were masked to treatment allocation but patients were aware of their group assignment. The primary endpoint was complete control, defined as no emetic episodes, no rescue medications, and no or mild nausea in the overall phase (0–120 hours), assessed in the modified intention-to-treat (mITT) population (ie, all eligible patients who received protocol-specified treatment, excluding those who had eligibility violations and who withdrew consent after randomisation). Daytime somnolence was the safety endpoint of interest. Non-inferiority was shown if the upper limit of the one-sided 95% CI for the difference in the complete control proportions between the treatment groups excluded the non-inferiority margin of 10%. This study is registered with the Clinical Trial Registry India, CTRI/2021/01/030233, is closed to accrual, and this is the final data analysis.
Results |
Between Feb 9, 2021, and May 30, 2023, 356 patients were pre-screened for eligibility, of whom 275 patients were enrolled and randomly assigned (134 to the 2·5 mg olanzapine group and 141 to the 10·0 mg olanzapine group). 267 patients (132 in the 2·5 mg group and 135 in the 10·0 mg group) were included in the mITT population, of whom 252 (94%) were female, 15 (6%) were male, and 242 (91%) had breast cancer. 59 (45%) of 132 patients in the 2·5 mg olanzapine group had complete control in the overall phase versus 59 (44%) of 135 in the 10·0 mg olanzapine group (difference –1·0% [one-sided 95% CI –100·0 to 9·0]; p=0·87). In the overall phase, there were significantly fewer patients in the 2·5 mg olanzapine group than in the 10·0 mg olanzapine group with daytime somnolence of any grade (86 [65%] of 132 vs 121 [90%] of 135; p<0·0001) and of severe grade on day 1 (six]5%] vs 54 [40%]; p<0·0001).
Interpretation |
Our findings suggest that olanzapine 2·5 mg is non-inferior to 10·0 mg in antiemetic efficacy and results in reduced occurrence of daytime somnolence among patients receiving highly emetic chemotherapy and should be considered as a new standard of care.
Funding |
Progressive Ladies Welfare Association.
Le texte complet de cet article est disponible en PDF.Plan
Vol 25 - N° 2
P. 246-254 - février 2024 Retour au numéro
Article précédent
- Effect of carvedilol versus placebo on cardiac function in anthracycline-exposed survivors of childhood cancer (PREVENT-HF): a randomised, controlled, phase 2b trial
- Saro H Armenian, Melissa M Hudson, Lanie Lindenfeld, Sitong Chen, Eric J Chow, Steven Colan, Willem Collier, Xiaohong Su, Edward Marcus, Meagan Echevarria, Aleksi Iukuridze, Leslie L Robison, F Lennie Wong, Ming Hui Chen, Smita Bhatia
- Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study
- Christian Pfister, Gwenaelle Gravis, Aude Flechon, Christine Chevreau, Hakim Mahammedi, Brigitte Laguerre, Aline Guillot, Florence Joly, Michel Soulie, Yves Allory, Valentin Harter, Stéphane Culine, VESPER Trial Investigators, Géraldine PIGNOT, Jean Philippe FENDLER, Laurent GUY, Grégory VERHOEST, Nicolas MOTTET, Arnaud DOERFLER, Sophie ABADIE LACOURTOISIE, Abde Rahmene AZZOUZI, Pierre MONGIAT, Lionnel GEOFFROIS, Pascal ESCHWEGE, Frédéric DI FIORE, Guilhem ROUBAUD, Jean Luc HOEPFFNER, Philippe BARTHELEMY, Hervé LANG, Eric VOOG, Eric MANDRON, Jean Marc TOURANI, Camille SERRATE, Alexandre COLAU, Carolina SALDANA, Alexandre DE LA TAILLE, Thierry NGUYEN, François KLEINCLAUSS, Yohan LORIOT, Jacques IRANI, Jean Christophe EYMARD, Stéphane LARRE, Olivier HUILLARD, Marc ZERBIB, Frédéric ROLLAND, Jérôme RIGAUD, Nadine HOUEDE, Stéphane DROUPY, Georgina MALOUF, Morgan ROUPRET, Sabine VIEILLOT, Nicolas LETANG, Tiffen LHARIDON, Nicolas GASCHIGNARD, Werner HILGERS, Jean Louis DAVIN
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?